araag2/HINT huggingface dataset:
Clinical trial NCT00580320 (phase 1, status: completed)
Conditions: melanoma, soft tissue sarcoma, parathyroid carcinoma, small cell carcinoma of the lung, carcinoid tumors
ICD codes: C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4, C46.1
Drugs: dacarbazine and bortezomib
SMILES: CN(C)\N=N\C1=C(N=CN1)C(N)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologic diagnosis of cutaneous or mucosal melanoma, soft tissue sarcoma (STS), or
             an APUD (amine precursor uptake and decarboxylation) tumor. APUD tumors include
             parathyroid carcinoma, medullary carcinoma of the thyroid, small cell carcinoma of the
             lung, pheochromocytoma, islet cell tumors, carcinoid tumors, and malignant
             paraganglioma.

          -  Measurable or evaluable disease not appropriate for resection and/or radiation with
             curative intent. Patients with small cell carcinoma must have extended stage disease
             or, if limited stage disease, must have received at least one prior systemic therapy.

          -  Age 18 years or greater

          -  ECOG Performance Status 0 or 1

          -  Women must be post-menopausal, infertile as the result of a surgical procedure, or
             willing to use a medically accepted form of birth control (abstinence, hormonal
             contraceptive, intra-uterine device, diaphragm with spermicide, condon with
             spermicide) for the duration of study treatment. Men also must agree to use a
             medically accepted form of birth control for the duration of study treatment.

        Exclusion Criteria:

          -  Uncontrolled brain metastatic disease

          -  Platelet count <100

          -  Absolute neutrophil count <1.5

          -  Blood transfusion or hematopoietic growth factors for cytopenia within one month of
             enrollment.

          -  Calculated or measured (Cockcroft and Gault formula) creatinine clearance <30
             mL/minute

          -  AST > 3 times the upper limit of normal, unless elevation due to metastatic disease,
             in which case AST > 5 times the upper limit of normal

          -  Bilirubin > 2 mg/mL

          -  Grade 2 or greater peripheral neuropathy

          -  Hypersensitivity to bortezomib, boron, mannitol, or dacarbazine

          -  Pregnant or nursing

          -  Other investigational drugs within 14 days of enrollment

          -  Other medical or other condition(s) that in the opinion of the
             investigator/sub-investigator might compromise the objectives of the study
Clinical trial NCT01202890 (phase 1, status: terminated)
Conditions: ovarian cancer, epithelial ovarian cancer, fallopian tube carcinoma, primary peritoneal carcinoma
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, H18.523, H18.521, H18.522, H18.529, C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31, C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: lenalidomide, liposomal doxorubicin, bevacizumab, revlimid, doxil, avastin
SMILES: NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O, NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O
Reason stopped: 
    terminated due to inadequate rate of accrual.
  
Eligibility criteria:

        Inclusion Criteria:

          -  EOC patients must be platinum resistant/refractory (see 1.1 for definition) and be
             considered by the attending physician capable of being treated in this study according
             to GCP.

          -  Measurable disease by RECIST criteria or evaluable disease by GCIC criteria

          -  No prior anthracycline or lenalidomide use, unless the dose received was equal or less
             than one cycle and the patient did not progress on treatment.

          -  Subjects must have calculated creatinine clearance > 60ml/min by Cockcroft-Gault
             formula during the escalation phase.

          -  Subjects must have calculated creatinine clearance ≥ 30ml/min by Cockcroft-Gault
             formula during the expansion phase. See section below, "Dosing Regimen", regarding
             lenalidomide dose adjustment for calculated creatinine clearance > 30ml/min and <
             60ml/min.

          -  Understand and voluntarily sign an informed consent form.

          -  All study participants must be registered into the mandatory RevAssist® program, and
             be willing and able to comply with the requirements of RevAssist®.

          -  Females of childbearing potential (FCBP)† must have a negative serum or urine
             pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days prior to
             and again within 24 hours of prescribing lenalidomide (prescriptions must be filled
             within 7 days) and must either commit to continued abstinence from heterosexual
             intercourse or begin TWO acceptable methods of birth control.

          -  No contraindication to anticoagulation

        Exclusion Criteria:

          -  Pregnant or breast feeding females. (Lactating females must agree not to breast feed
             while taking lenalidomide).

          -  Concurrent use of other anti-cancer agents or treatments.

          -  Known seropositive for or active viral infection with human immunodeficiency virus
             (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV). Patients who are
             seropositive because of hepatitis B virus vaccine are eligible.

          -  History of thromboembolic event within the last 3 months

          -  Known hypersensitivity to any component of Avastin
Clinical trial NCT00373815 (phase 1, status: terminated)
Conditions: graft versus host disease
ICD codes: D89.810, D89.811, D89.813, D89.812
Drugs: everolimus
SMILES: [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Reason stopped: 
    high incidence of ttp, poor recrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Written informed consent prior to inclusion into the study

          -  Allogeneic HSCT from HLA-identical related or unrelated donors

          -  Clinically confirmed acute GVHD ≥ grade II

          -  Age < 70 / > 18 years, male or female

          -  Karnofsky performance status > 60 %

        Exclusion Criteria:

          -  Oral treatment is not feasible

          -  Severe hepatic impairment Child-Pugh C

          -  Active cerebral epilepsy

          -  Renal failure (Creatinine clearance < 50 ml/min)

          -  Life expectancy < 3 months

          -  Known hypersensitivity to everolimus, sirolimus or to any of the excipients

          -  Confirmed pregnancy (serum β-HCG)

          -  Non-effective contraception for both, male and female patients, if the risk of
             conception exists

          -  Patients with limited legal capacity

          -  Patients unwilling and unable to undergo study procedures
Clinical trial NCT00148902 (phase 1, status: completed)
Conditions: neoplasms, breast
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: lapatinib, docetaxel
SMILES: CN(C1=CC2=NN(C)C(C)=C2C=C1)C1=CC=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=N1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Advanced solid tumors.

          -  Able to swallow oral medication.
Clinical trial NCT00516165 (phase 1/phase 2, status: completed)
Conditions: hepatocellular carcinoma
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: rad001
SMILES: [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](O)[C@@H](C1)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Unresectable of metastatic HCC. Patients must have prior core biopsy to confirm the
             diagnosis of HCC and have archived tissues available for correlative studies

          -  At least one measurable site of disease according to RECIST criteria that has not been
             previously irradiated. If it has had previous radiation to teh marker lesion(s), there
             must be evidence of progression since the radiation

          -  0-2 prior systemic chemotherapy and biologic regimens for hepatocellular carcinoma

          -  Patients with prior chemoembolization history can participate in the study if the
             chemoembolization was performed more than 4 weeks ago and patients must have
             measurable disease outside of prior chemoembolization field

          -  18 years of age or older

          -  Minimum of 4 weeks since any major surgery or completion of radiation

          -  Minimum of 4 weeks since completion of all prior systemic anticancer therapy

          -  ECOG performance status of 0-2

          -  CLIP score of equal to or less then 3

          -  Adequate bone marrow, liver and renal function as outlined in the protocol

        Exclusion Criteria:

          -  Prior treatment with any investigational drug within the preceding 4 weeks

          -  Chronic treatment with systemic steroids or another immunosuppressive agent

          -  Uncontrolled brain or leptomeningeal metastases, including patients who continue to
             require glucocorticoids for brain or leptomeningeal metastases

          -  Patients with any severe and/or uncontrolled medical conditions or other condition
             that could affect participation in the study

          -  Known history of HIV seropositivity

          -  Impairment of gastrointestinal function or gastrointestinal disease that may
             significantly alter the absorption of RAD001

          -  Active, bleeding diathesis

          -  Women who are pregnant or breast feeding

          -  Patients who have received prior treatment with an mTor inhibitor

          -  Patients with known hypersensitivity to RAD001 or other rapamycins or its excipients

          -  History of non-compliance to medical regimens

          -  Patients with a positive dipstick for urine protein (reading of 2+ or greater) will
             then undergo a 24-hour urine collection for protein. If patients have a 2g or greater
             of protein/24hr, they will be excluded from the study.
Clinical trial NCT00084890 (phase 1, status: terminated)
Conditions: cervical cancer
ICD codes: M50.20, M50.21, M50.30, M50.31, M50.80, M50.81, M50.90
Drugs: carboplatin, docetaxel
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed squamous cell carcinoma of the uterine cervix

               -  Advanced disease (stage IVB)

               -  Persistent or recurrent disease

          -  No available curative treatment options

          -  Measurable disease by physical examination, chest x-ray, CT scan, or MRI

        PATIENT CHARACTERISTICS:

        Age

          -  Over 18

        Performance status

          -  GOG 0-2

        Life expectancy

          -  More than 6 months

        Hematopoietic

          -  Absolute neutrophil count > 1,500/mm^3

          -  Platelet count > 100,000/mm^3

          -  Hemoglobin > 8 g/dL

        Hepatic

          -  Bilirubin normal

          -  SGOT and SGPT ≤ 2.5 times upper limit of normal (ULN) AND alkaline phosphatase normal
             OR

          -  Alkaline phosphatase ≤ 4 times ULN AND SGOT and SGPT normal

        Renal

          -  Creatinine < 1.5 times ULN

        Other

          -  No other invasive malignancy within the past 5 years

          -  No prior severe hypersensitivity reaction to docetaxel or other drugs formulated with
             polysorbate 80

          -  No peripheral neuropathy > grade 1

          -  No other concurrent malignancy except curatively treated non-melanoma skin cancer

          -  No other serious medical or psychiatric illness that would preclude giving informed
             consent or limit survival

          -  Not pregnant

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for 6 months after study
             participation

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No concurrent biologic therapy

        Chemotherapy

          -  No more than 2 prior chemotherapy regimens

               -  One sensitizing chemotherapy regimen during radiotherapy AND 1 regimen for
                  recurrent disease are considered 2 regimens

          -  At least 4 weeks since prior chemotherapy

          -  No prior docetaxel

          -  No prior carboplatin

          -  No other concurrent chemotherapy

        Endocrine therapy

          -  At least 4 weeks since prior hormonal therapy

        Radiotherapy

          -  See Chemotherapy

          -  At least 4 weeks since prior radiotherapy

          -  No concurrent radiotherapy

        Surgery

          -  At least 3 weeks since prior major surgery
Clinical trial NCT00646165 (phase 1, status: terminated)
Conditions: b-cell chronic lymphocytic leukemia
ICD codes: C91.11, C91.12, C91.10
Drugs: forodesine
SMILES: OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)C1=CNC2=C1N=CNC2=O
Reason stopped: 
    poor recruitment and change in development strategy
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with confirmed Binet Stage B or C B-CLL as defined by the National Cancer
             Institute (NCI) sponsored working group who have received up to 2 previous lines of
             treatment, one of which was fludarabine based. The two previous treatments could have
             included combination therapies.

          -  Patients must be ≥18 years of age, have a life expectancy of >6 months, and an Eastern
             Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2. - Female patients
             must not be pregnant (as confirmed by negative pregnancy test for women of
             childbearing potential) and female and male patients must be willing to use effective
             contraception for the entire duration of treatment and 2 months thereafter.

        Exclusion Criteria:

          -  Patients who have received more than 2 previous lines of treatment will be excluded
             from this study.

          -  Additional groups of patients who may not participate in the study include: patients
             who are pregnant and/or nursing; patients on corticosteroid treatment; patients with
             active infection (bacterial, viral or fungal) or severe infection (WHO 4th degree)
             within the last 3 months; patients with total bilirubin > 2 × ULN; patients with
             calculated creatinine clearance <70 mL/min; patients with seropositivity for human
             immunodeficiency virus, hepatitis B virus, or hepatitis C virus; patients with any
             coexisting medical or psychological condition that would preclude participation in the
             required study procedures; patients who have participated in another clinical study <6
             weeks prior to this study; or patients with a known hypersensitivity to the study
             medication.
Clinical trial NCT00469209 (phase 1/phase 2, status: completed)
Conditions: myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: trisenox (arsenic trioxide), velcade (bortezomib), melphalan, vitamin c (ascorbic acid)
SMILES: O=[As]O[As]=O, CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=CN=CC=N1)B(O)O, N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O, [H][C@@]1(OC(=O)C(O)=C1O)[C@@H](O)CO
Eligibility criteria:

        Inclusion Criteria:

          1. a) Primary Refractory Disease (defined as failure to achieve even a partial response
             to induction therapy) b) Consolidation of a partial remission (defined as a decrease
             but continued presence of monoclonal protein on serum and urine immunofixation
             electrophoresis, and/or the presence of plasmacytosis on bone marrow aspirate and
             biopsy) c) Relapsing after prior therapy (disease relapsing after achieving a partial
             or complete response to prior conventional or high-dose therapy).

          2. Age up to 75 years.

          3. Zubrod performance status of <2.

          4. Left ventricular ejection fraction >40%. No uncontrolled arrhythmias or symptomatic
             cardiac disease.

          5. Forced expiratory volume (FEV1), forced volume vital capacity (FVC) and Diffusing
             Capacity of the Lung for Carbon Monoxide (DLCO) >40%. No symptomatic pulmonary
             disease.

          6. Serum bilirubin <2 times upper limit of normal, alanine aminotransferase/SGPT <4 times
             upper limit of normal. No evidence of chronic active hepatitis or cirrhosis. No
             effusion or ascites >1L prior to drainage.

          7. HIV-negative.

          8. Negative Beta human chorionic gonadotrophin (hCG) test in a woman with child bearing
             potential, defined as not post-menopausal for 12 months or no previous surgical
             sterilization

          9. Patient or guardian able to sign informed consent

         10. Corrected QT interval less than 470 msec.

        Exclusion Criteria:

          1. Corrected QT interval greater than 470 msec.

          2. Patients in complete remission (defined as the absence of monoclonal protein on serum
             and urine immunofixation electrophoresis, and the absence of plasmacytosis in bone
             marrow aspirate and biopsy).

          3. Patients with non-secretory myeloma.
Clinical trial NCT00706030 (phase 1/phase 2, status: completed)
Conditions: breast cancer, advanced malignant solid tumors
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: neratinib, vinorelbine
SMILES: CCOC1=C(NC(=O)\C=C\CN(C)C)C=C2C(NC3=CC=C(OCC4=CC=CC=N4)C(Cl)=C3)=C(C=NC2=C1)C#N, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Confirmed pathologic diagnosis of a solid tumor that is not curable with available
             therapies for which HKI-272 plus vinorelbine is a reasonable treatment option (part 1
             only) or Confirmed pathologic diagnosis of ErbB-2-positive breast cancer (current
             stage IV) in female subjects for which vinorelbine plus HKI-272 is a reasonable
             treatment option (part 2 only).

          -  At least 1 prior antineoplastic chemotherapy treatment regimen for metastatic disease
             and at least 1 prior treatment with a trastuzumab-containing regimen for at least 6
             weeks, for metastatic disease or subject relapsing under adjuvant treatment (part 2
             only).

          -  At least 1 measurable lesion as defined by Response Evaluation Criteria in Solid
             Tumors (RECIST).

        Exclusion Criteria:

          -  More than 2 prior antineoplastic treatment regimens (excluding hormonotherapy) for
             metastatic disease. Subjects who relapsed under adjuvant treatment shouldn't have
             received more than one line of chemotherapy for metastatic disease (part 2 only).

          -  Prior treatment with vinorelbine for metastatic setting, or prior treatment with any
             ErbB-2 targeted agents except trastuzumab (part 2 only). Up to 20 subjects with
             ErbB-2-overexpressing metastatic breast cancer who have been previously exposed to
             lapatinib but are not refractory to lapatinib may be enrolled in part 2.

          -  Prior treatment with anthracyclines with a cumulative dose of doxorubicin of greater
             than 400 mg/m2, or of epirubicin dose of greater than 800 mg/m2, or the equivalent
             dose for other anthracyclines or derivatives (part 2 only).
Clinical trial NCT00308269 (phase 1, status: completed)
Conditions: cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: vintafolide iv bolus, vintafolide iv infusion
SMILES: [H][C@@]12N3CC[C@@]11C4=CC(=C(OC)C=C4N(C)[C@@]1([H])[C@](O)([C@H](O)[C@]2(CC)C=CC3)C(=O)NNC(=O)OCCSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)CC[C@H](NC(=O)C1=CC=C(NCC2=CNC3=NC(N)=NC(=O)C3=N2)C=C1)C(O)=O)C(O)=O)[C@]1(C[C@@]2([H])C[N@](C[C@](O)(CC)C2)CCC2=C1NC1=CC=CC=C21)C(=O)OC, [H][C@@]12N3CC[C@@]11C4=CC(=C(OC)C=C4N(C)[C@@]1([H])[C@](O)([C@H](O)[C@]2(CC)C=CC3)C(=O)NNC(=O)OCCSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)CC[C@H](NC(=O)C1=CC=C(NCC2=CNC3=NC(N)=NC(=O)C3=N2)C=C1)C(O)=O)C(O)=O)[C@]1(C[C@@]2([H])C[N@](C[C@](O)(CC)C2)CCC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Histological or cytological diagnosis of neoplasm

          -  No effective standard therapeutic options

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

          -  >=4 weeks post therapeutic radiation of chemotherapy >=6 weeks for nitrosoureas and
             mitomycin C) and recovery from associated toxicities

          -  Negative serum pregnancy test for women of child-bearing potential and willingness to
             practice contraceptive methods

          -  Adequate bone marrow reserve, renal, and hepatic function

        Exclusion Criteria:

          -  Concurrent hematological malignancies

          -  Women who are pregnant or lactating

          -  Evidence of symptomatic brain metastases

          -  Receiving concomitant anticancer therapy (excluding supportive care)

          -  Requires palliative radiotherapy at time of study entry
Clinical trial NCT01802697 (phase 1, status: completed)
Conditions: healthy
ICD codes: Z76.3, Z76.2
Drugs: ides, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Ability to understand and sign informed consent

          -  BMI 19-30

        Exclusion Criteria:

          -  Clinically significant disease

          -  Positive HIV, hepatistis B or C

               -  Drug abuse

          -  Smoking

          -  Use of medication except paracetamol
Clinical trial NCT00558571 (phase 1, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: bi 10773 low dose, placebo to bi 10773, bi 10773 medium dose, bi 10773 high dose
SMILES: [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1, [H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Male and postmenopausal or hysterectomised female patients with type 2 diabetes

          -  Age >18 and < 70 years

          -  BMI >18.5 and <40 kg/m2

        Exclusion Criteria:

          -  Antidiabetic treatment with insulin or glitazones or with more than one oral
             hypoglycaemic agent;

          -  Fasted blood glucose > 240 mg/dl (>13.3 mmol/L) or a blood glucose level above 400
             mg/dl (22.2 mmol/L) postprandially;

          -  HbA1c > 8.5 %